Neumora Therapeutics/$NMRA
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Neumora Therapeutics
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Ticker
$NMRA
Sector
Primary listing
Employees
92
Headquarters
Website
NMRA Metrics
BasicAdvanced
$169m
-
-$1.32
2.76
-
Price and volume
Market cap
$169m
Beta
2.76
52-week high
$3.65
52-week low
$0.72
Average daily volume
1.7m
Financial strength
Current ratio
5.095
Quick ratio
4.884
Long term debt to equity
75.102
Total debt to equity
75.514
Interest coverage (TTM)
-42.99%
Profitability
EBITDA (TTM)
-218.025
Effective tax rate (TTM)
-0.02%
Management effectiveness
Return on assets (TTM)
-66.39%
Return on equity (TTM)
-148.74%
Valuation
Price to book
2.36
Price to tangible book (TTM)
2.36
Price to free cash flow (TTM)
-0.794
Free cash flow yield (TTM)
-125.88%
Free cash flow per share (TTM)
-1.151
Growth
Earnings per share change (TTM)
-17.79%
3-year earnings per share growth (CAGR)
-33.03%
NMRA News
AllArticlesVideos
Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail
Benzinga·2 days ago
Neumora Therapeutics scraps depression drug after two late-stage trial failures
Reuters·2 days ago
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs